Sign in
CompletedNo phase

Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery

Key facts

Who runs it
Indiana University
Where
Indianapolis, United StatesSee the site
Trial code
Status
Completed
People taking part
209 people enrolled
Started
10 Dec 2018
Ended
12 Sept 2024
Type of study
Observational
Record updated
18 December 2024

Who can take part

Age
30 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Male or female patients 30 years or older planning to undergo weight reduction surgery or planning to enter into a physician monitored weight loss program
  • Patients must be obese, defined as a BMI ≥ 30 as calculated by the formula:; weight in pounds / height squared x 703 = BMI
  • Subject consent and authorization for the release of health information must be obtained according to local institutional guidelines
  • To remain in the study for the follow-up phase, the baseline screening test must indicate that a patient has MGUS

Who cannot take part

  • No history of any malignancy except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years
  • No concurrent or planned participation in randomized trials of weight loss
  • A patient will be excluded from the follow-up phase if the baseline screening test indicates they do not have MGUS

Where in United States

  • Indiana University Simon Cancer CenterIndianapolis, United States

About the trial

What the trial wants to find out

Screening study to determine incidence of MGUS in this patient population

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective Observation of the Incidence and Natural History of Monoclonal Gammopathy in Patients Undergoing Weight Reduction Surgery
Record updated
18 December 2024